큐어러티브 바이오테크놀로지(CUBT)는 NYSE MKT에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.93 (-7.49%), 시가총액 $0.01B, 52주 범위 $0.65 ~ $2.25.
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine. Curative
큐어러티브 바이오테크놀로지의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
큐어러티브 바이오테크놀로지의 현재 주가는 $0.93 (-7.49%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
큐어러티브 바이오테크놀로지의 시가총액은 약 $0.01B입니다.
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformul